|February 18, 2014|
|07:36 EDT||NAVB||Navidea announces priority review for sNDA to expand Lymphoseek labeling|
Navidea Biopharmaceuticals announced that the U.S. Food and Drug Administration has accepted the Supplemental New Drug Application and granted a Priority Review for the expanded use of Lymphoseek Injection indicated for sentinel lymph node detection in patients with head and neck cancer. Under the Prescription Drug User Fee Act, the FDA has set a target review date for the Lymphoseek sNDA of June 16. The FDA grants priority review status to drug applications that may offer a significant improvement in treatment over existing options. Lymphoseek is currently approved for use in lymphatic mapping procedures performed to aid in the diagnostic evaluation of lymph nodes draining a primary tumor in patients with breast cancer and melanoma.
News For NAVB From The Last 14 Days
|September 3, 2015|
|07:32 EDT||NAVB||Navidea awarded $1.8M grant for evaluation of Manocept agent in Kaposi's Sarcoma|
Subscribe for More Information
|September 2, 2015|
|07:33 EDT||NAVB||Navidea announces dual listing on Tel Aviv Stock Exchange|
Navidea Biopharmaceuticals announced that the Tel Aviv Stock Exchange has approved the new listing of Navidea's common stock on the TASE beginning on Tuesday, September 8 under the ticker symbol NAVB. The company's common stock will be listed on both the NYSE MKT in the United States and the TASE in Israel. The company also announced that, based upon Navidea's current market capitalization, it expects its shares to be subject to inclusion in five TASE equity indexes.
|07:27 EDT||NAVB||Sidoti to hold a conference|
2015 Sidoti Emerging Growth Conference is being held in New York on September 2.
|August 24, 2015|
|07:32 EDT||NAVB||Navidea to register shares for dual listing on TASE|
Navidea Biopharmaceuticals announced that it has filed an application for registration of shares of its common stock for dual listing on the Tel-Aviv Stock Exchange, or TASE. Dual listing on the TASE is allowed in the U.S. and Israel without any additional regulatory requirements for companies whose shares are listed on certain accredited stock exchanges outside of Israel, including the NYSE MKT.